English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: Alpha-fetoprotein (AFP) is an oncofetal antigen during hepatocellular carcinoma (HCC) development which could lead to weak reproducible antitumor immunity, and may act as a target for cancer therapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. The study is intended to develop a specific anti-tumor peptide vaccine-heat shock protein 72 (HSP72) and alpha-fetoprotein epitope peptide (AFP-P). Methods: By way of glutaraldehyde cross-linking, we constructed a potential therapeutic peptide vaccine, HSP72/AFP-P. In vitro and in vivo cytotoxicity assays were used to verify anti-tumor effect of the recombined vaccine. Results: The results showed that cross-linking of AFP epitope peptide with HSP72 induced significant enhancement in specific AFP CD8 T cells response and distinct cytotoxic antitumor reaction against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Conclusion: Our study suggests that tumor vaccination through cross-linking tumor antigen and HSP72 is an encouraging method for cancer immunotherapy. Keywords-Heat Shock Protein 72 (HSP72); AlphaFetoprotein (AFP); Vaccine; Tumor; Immunotherapy

Anti-tumor Immunity Induced by Heat Shock Protein 72 and Alpha-fetoprotein Epitope Peptide Vaccine